Answers are grounded in this paper and cite their sources.
Machine learning predicts distant recurrence in early breast cancer, suggesting personalized treatment decisions using real-world data.
Purpose: Despite current standard-of-care endocrine therapy, distant recurrence remains a concern for patients with HR+/HER2− early breast cancer (EBC). Understanding individual recurrence risk would aid in clinical decision making. We used machine learning to identify risk factors and develop recurrence risk prediction models. Experimental Design: Predictor variables were identified by gradient boosting and used to train models on a large, diverse real-world dataset of patients with stage I–III HR+/HER2− EBC obtained from the US-based, electronic health record-derived deidentified Flatiron Health Research Database. An elastic net–penalized Cox proportional hazards model was validated internally with real-world data and externally with data from the NATALEE trial of ribociclib in patients with HR+/HER2− EBC. Prediction and outcome concordance for distant recurrence and treatment effect were analyzed with Harrell’s concordance index (C-index) and integrated Brier score (IBS); model performance over time was determined by dynamic AUC analysis. Results: The model accurately predicted distant recurrence in the real-world cohort (n=7842; C-index: 0.85 [95% CI: 0.8461–0.8598]; IBS: 0.05 [95% CI: 0.0443–0.0495]) over time (AUC >0.7 through 10 years); internal validation and sensitivity analyses confirmed model performance. External validation with the NATALEE NSAI alone arm yielded a lower but still discriminative performance (C-index: 0.66). Training on NATALEE data improved concordance (C-index: 0.70); the NATALEE-trained model predicted a 3.2% reduction in distant recurrence at 48 months with ribociclib treatment in the real-world cohort. Conclusion: A machine learning model was developed that accurately predicted distant recurrence in HR+/HER2− EBC. The identified predictor variables and developed models may aid risk-based personalized treatment decision making.
No takes yet. Share an insight, caveat, or question.
Howard et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: